drugset / Trial / NCT02667938

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

NCT02667938

Phase 3 Completed 510 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction

Timeline

Start
2015-03
Primary completion
2016-01
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject HCP1303 Unknown 0.2 mg
Subject HCP1303 Unknown 0.4 mg
Comparator HGP1201 Unknown